← Leaderboards
James Christopher Costello
University Of Colorado Denver
$5,052,235
Attributed
$9,592,876
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,592,876 · 7
By mechanism
R01$5,397,417 · 2
U01$3,364,869 · 1
R21$439,248 · 1
T32$340,192 · 1
R13$51,150 · 2
Top collaborators
- Scott D Cramer5 shared
- Dan Theodorescu5 shared
- Casey S Greene2 shared
- Svitlana Tyekucheva2 shared
- Jason Aoto1 shared
- Mark L Dell'Acqua1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Daniel V. Labarbera$3,658,170
- Christine M Swanson$2,768,259
- Frank J. Accurso$3,381,974
- Sean P Colgan$26,539,753
- Megan L Goodall$123,629
Others in their field
Other Emerging Leaders on “Genes”
- Leonard Freedman · Leidos Biomedical Research, Inc.$97,908,773
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,311,588
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Evan Z Macosko · Broad Institute, Inc.$32,734,698
Research focus
GenesTumorAffectGrowthMalignant NeoplasmsPrognostic MarkerIn VivoPre-ClinicalPhenotypeCancer CellCellsTumor GrowthMolecularTumor Suppressor ProteinsPharmaceutical PreparationsIn VitroData SetComplexKidneyCancer PatientTherapeutic TargetNovel StrategiesAutomobile DrivingSite
Grant awards (18)
Novel computational strategies to deconvolute co-occurring conditions in Down syndrome$893,680
R01 · FY2025 · HD · contact PI
NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer$573,842
R01 · FY2025 · CA · contact PI
Predoctoral Training Grant in Pharmacology and Molecular Medicine$340,192
T32 · FY2025 · GM · contact PI
NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer$476,566
R01 · FY2024 · CA
NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer$80,996
R01 · FY2024 · CA
Systems Approaches to Cancer Biology Meeting$25,400
R13 · FY2024 · CA · contact PI
Investigating NPEPPS-mediated feedback between bladder cancer cells and peripheral neurons as a mechanism of cisplatin resistance$9,180
R01 · FY2024 · CA
Systems analysis of aggressive prostate cancer pathology$598,524
U01 · FY2023 · CA · contact PI
NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer$491,617
R01 · FY2023 · CA
Novel computational strategies to deconvolute co-occurring conditions in Down syndrome$2,353,137
R01 · FY2022 · HD · contact PI
Systems analysis of aggressive prostate cancer pathology$794,056
U01 · FY2022 · CA · contact PI
NPEPPS is a novel and druggable determinant of chemotherapy resistance in bladder cancer$518,399
R01 · FY2022 · CA
Systems Approaches to Cancer Biology Meeting$25,750
R13 · FY2022 · CA · contact PI
Systems analysis of aggressive prostate cancer pathology$610,738
U01 · FY2021 · CA · contact PI
Curated prostate cancer data for novel and reproducible prognostic modeling$173,649
R21 · FY2021 · CA
Systems analysis of aggressive prostate cancer pathology$745,463
U01 · FY2020 · CA · contact PI
Curated prostate cancer data for novel and reproducible prognostic modeling$265,599
R21 · FY2020 · CA
Systems analysis of aggressive prostate cancer pathology$616,088
U01 · FY2019 · CA · contact PI